Drugs / DCSZ11
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05785754 | Jun 2023 → Dec 2026 expected | — | DynamiCure Biotechnology | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07035249 | Dec 2025 → Jun 2027 expected | head and neck squamous cell carcinoma | West China Hospital | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07580339 | Jul 2026 → Jul 2030 expected | rectal cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCSZ11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07035249 ↗ |
| Action | Inhibit | “CD93 Inhibition (DCSZ11)” NCT07580339 ↗ |
| Modality | Monoclonal antibody | “A monoclonal antibody that binds to CD93” NCT05785754 ↗ |
| Route | Intravenous | “single intravenous (IV) infusion” NCT05785754 ↗ |
| Target | CD93 | “A monoclonal antibody that binds to CD93” NCT05785754 ↗ |